Directory Hormones and their antagonists Adrenal Glukokortikoida Benakort
This page is translated automatically with a help of Google Translate

Benakort

See also Budesonide

Roman name

Benacort

The composition and the form of

one dose powder inhalations budesonida contains 200 µ g, as well as sodium benzoate 9.8 mg; in inhalers ziklohaler 100 or 200 doses, in a carton 1 pc.

Characteristics

Melkochristalliceski powder white, or nearly white.

Of drugs

Противовоспалительно е. Oppressing synthesis lakotrienov and NG products Cytokines, suppressing the inflammatory process in the walls of the bronchi, consequential T-limfozitami.

Farmakodinamika

Impact giperreaguosti bronchi, improves lung function and mukotiliarnyi Cl. Provides local view противовоспалительно е Effects. And protivogribkova (fungicidal) activity and helpful to patients (sodium benzoate).

Indications

Bronchial asthma (prevention and treatment), including : against fungal disease mucous membranes of the oral cavity and bronchi.

Pregnancy and lactation

Perhaps only after consultation with the doctor.

Contraindications

Гиперчувствительност ь.

Side-Effects

Local : rarely ohriplosti vote, and sometimes cough (through inappropriate technology inhalation).

Patient interaction

Adrenomimetiki (salbutamol, etc.) increased effect.

Dosing and Administration

Inhalation, using a portable ingalatora ziklohaler. Under the dose of 200 micrograms, daily-prepared individually in the light of the gravity of the disease and supporting dose glucocorticoids tablets; Frequency reception from 2 to 4 inhalations per day. Initial daily intake - time 2-8 doses per day (400-1600 µ g), maintenance treatment-1-4 doses per day (800 g) in the period increased from 4 to 8 doses per day. After reaching effects should not be drastically cut treatment (dose to be reduced progressively). Be wary appoint patients with pulmonary tuberculosis disease in chicken. It eliminates asthma status. While receiving corticosteroid inwards on treatment Benakortom be in a stable phase of the disease combining with inhalation oral therapy for 14-20 days, then gradually reduce the dose for admission into the complete elimination (if possible).

Storage conditions

por.d / ingal.doz. : List B. In dry the dark place at a temperature of no higher than 25 ° C

Shelf life

por.d / ingal.doz. : 3 and

All products of this group

0